• Vaxcyte priced USD 500 million of 1.50% convertible senior notes due 2032.
• Initial conversion price set at USD 89.60 per share, a 40% premium to the USD 64.00 stock offering price.
• Notes accrue interest semi-annually starting April 15, 2027; maturity set for Oct. 15, 2032.
• Underwriters hold a 30-day option to buy up to an additional USD 75 million of notes for over-allotments.
• Closing expected Oct. 9, 2026, subject to customary conditions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vaxcyte Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610062248PRIMZONEFULLFEED9841187) on October 07, 2026, and is solely responsible for the information contained therein.